Company intelligence / Profile preview
SOFAR
- Ownership
- Private
- Employees
- ~300
- Development stage
- Commercial
Overview
SOFAR has a long-standing commercial presence with over 150 marketed products in more than 10 therapeutic areas. Its portfolio is especially strong in gastrointestinal health and probiotics/microbiota research. The company’s leading brands include Pentacol (for IBD), Enterolactis (probiotic), Gerdoff (gastroesophageal reflux), Cistiflux and Siler (gynecology/urology). Clinical results are not typically published for supplements/devices but the company is recognized for high-quality standards and innovation[1][2][3][6].
- Therapeutic areas
- GastroenterologyMen's HealthDermatologyOtherWomen's Health
- Modalities
- Small moleculeProbiotic (Live biotherapeutic product therapy)Medical deviceDietary supplement
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on SOFAR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOFAR.